Fatty acid metabolism and its longitudinal relationship with the hypothalamic-pituitary-adrenal axis in major depression: Associations with prospective antidepressant response

Psychoneuroendocrinology

Volumn 59, Issue , 2015, Pages 1-13

  Mocking, Roel J T ^a   Verburg, Hanka F ^a   Westerink, Anne M ^a   Assies, Johanna ^a   Vaz, Frédéric M ^c   Koeter, Maarten W J ^a   Ruhé, Henricus G ^a,b   Schene, Aart H ^a,d,e  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e RADBOUD UNIVERSITY   (Netherlands)

Author keywords

Cortisol; Docosahexaenoic acid; Eicosapentaenoic acid; Fatty acids; Major depressive disorder; n 3 PUFA; Paroxetine; Prognosis; Serotonin uptake inhibitors

Indexed keywords

DOCOSAHEXAENOIC ACID; HYDROCORTISONE; ICOSAPENTAENOIC ACID; PAROXETINE; PLACEBO; FATTY ACID;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; ERYTHROCYTE MEMBRANE; FATTY ACID ANALYSIS; FATTY ACID DESATURATION; FATTY ACID METABOLISM; FEMALE; FISH; FOOD INTAKE; HAMILTON DEPRESSION RATING SCALE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LIPID PEROXIDATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SALIVA LEVEL; TREATMENT DURATION; TREATMENT RESPONSE; CASE CONTROL STUDY; CROSS-SECTIONAL STUDY; DEPRESSIVE DISORDER, MAJOR; DOSE RESPONSE; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LIPID METABOLISM; METABOLISM; SALIVA;

ADULT; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DEPRESSIVE DISORDER, MAJOR; DOCOSAHEXAENOIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EICOSAPENTAENOIC ACID; FATTY ACIDS; FEMALE; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LIPID METABOLISM; LONGITUDINAL STUDIES; MALE; PAROXETINE; PITUITARY-ADRENAL SYSTEM; SALIVA;

EID: 84937420153     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2015.04.027     Document Type: Article

References (59)

1. Able J.A., Liu Y., Jandacek R., Rider T., Tso P., McNamara R.K. Omega-3 fatty acid deficient male rats exhibit abnormal behavioral activation in the forced swim test following chronic fluoxetine treatment: association with altered 5-HT1A and alpha2A adrenergic receptor expression. J. Psychiatr. Res. 2014, 50:42-50.
2. Albanese E., Lombardo F.L., Dangour A.D., Guerra M., Acosta D., Huang Y., Jacob K.S., Llibre Rodriguez Jde J., Salas A., Schonborn C., Sosa A.L., Williams J., Prince M.J., Ferri C.P. No association between fish intake and depression in over 15,000 older adults from seven low and middle income countries - the 10/66 study. PLoS ONE 2012, 7:e38879.
3. Andreeva V.A., Galan P., Torres M., Julia C., Hercberg S., Kesse-Guyot E. Supplementation with B vitamins or n-3 fatty acids and depressive symptoms in cardiovascular disease survivors: ancillary findings from the SUpplementation with FOLate, vitamins B-6 and B-12 and/or OMega-3 fatty acids (SU.FOL.OM3) randomized trial. Am. J. Clin. Nutr. 2012, 96:208-214.
4. Appleton K.M., Rogers P.J., Ness A.R. Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am. J. Clin. Nutr. 2010, 91:757-770.
5. Assies J., Mocking R.J., Lok A., Ruhé H.G., Pouwer F., Schene A.H. Effects of oxidative stress on fatty acid- and one-carbon-metabolism in psychiatric and cardiovascular disease comorbidity. Acta Psychiatr. Scand. 2014, 130:163-180.
6. Assies J., Pouwer F., Lok A., Mocking R.J., Bockting C.L., Visser I., Abeling N.G., Duran M., Schene A.H. Plasma and erythrocyte fatty acid patterns in patients with recurrent depression: a matched case-control study. PLoS ONE 2010, 5:e10635.
7. Basselin M., Ramadan E., Rapoport S.I. Imaging brain signal transduction and metabolism via arachidonic and docosahexaenoic acid in animals and humans. Brain Res. Bull. 2012, 87:154-171.
8. Bazinet R.P., Laye S. Polyunsaturated fatty acids and their metabolites in brain function and disease. Nat. Rev. Neurosci. 2014, 15:771-785.
9. Bloch M.H., Hannestad J. Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Mol. Psychiatry 2012, 17:1272-1282.
10. Bockting C.L., Mocking R.J., Lok A., Koeter M.W., Schene A.H. Therapygenetics: the 5HTTLPR as a biomarker for response to psychological therapy?. Mol. Psychiatry 2013, 18:744-745.
11. Chalon S. Omega-3 fatty acids and monoamine neurotransmission. Prostaglandins Leukot. Essent. Fatty Acids 2006, 75:259-269.
12. Deuschle M., Hamann B., Meichel C., Krumm B., Lederbogen F., Kniest A., Colla M., Heuser I. Antidepressive treatment with amitriptyline and paroxetine: effects on saliva cortisol concentrations. J. Clin. Psychopharmacol. 2003, 23:201-205.
13. Dinan T., Siggins L., Scully P., O'Brien S., Ross P., Stanton C. Investigating the inflammatory phenotype of major depression: focus on cytokines and polyunsaturated fatty acids. J. Psychiatr. Res. 2009, 43:471-476.
14. Evans J.M. Re: "Longitudinal associations between fish consumption and depression in young adults". Am. J. Epidemiol. 2014, 180:557.
15. Fabbri C., Marsano A., Balestri M., De Ronchi D., Serretti A. Clinical features and drug induced side effects in early versus late antidepressant responders. J. Psychiatr. Res. 2013, 47:1309-1318.
16. Fiedorowicz J.G., Hale N., Spector A.A., Coryell W.H. Neuroticism but not omega-3 fatty acid levels correlate with early responsiveness to escitalopram. Ann. Clin. Psychiatry 2010, 22:157-163.
17. Fisar Z. Interactions between tricyclic antidepressants and phospholipid bilayer membranes. Gen. Physiol. Biophys. 2005, 24:161-180.
18. Fisar Z., Anders M., Tvrzicka E., Stankova B. Effect of long-term administration of antidepressants on the lipid composition of brain plasma membranes. Gen. Physiol. Biophys. 2005, 24:221-236.
19. Gertsik L., Poland R.E., Bresee C., Rapaport M.H. Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder. J. Clin. Psychopharmacol. 2012, 32:61-64.
20. Harris W.S., Pottala J.V., Sands S.A., Jones P.G. Comparison of the effects of fish and fish-oil capsules on the n 3 fatty acid content of blood cells and plasma phospholipids. Am. J. Clin. Nutr. 2007, 86:1621-1625.
21. Hibbeln J.R., Salem N. Dietary polyunsaturated fatty acids and depression: when cholesterol does not satisfy. Am. J. Clin. Nutr. 1995, 62:1-9.
22. Jazayeri S., Keshavarz S.A., Tehrani-Doost M., Djalali M., Hosseini M., Amini H., Chamari M., Djazayery A. Effects of eicosapentaenoic acid and fluoxetine on plasma cortisol, serum interleukin-1beta and interleukin-6 concentrations in patients with major depressive disorder. Psychiatry Res. 2010, 178:112-115.
23. Jazayeri S., Tehrani-Doost M., Keshavarz S.A., Hosseini M., Djazayery A., Amini H., Jalali M., Peet M. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Aust. N. Z. J. Psychiatry 2008, 42:192-198.
24. Kaddurah-Daouk R., Bogdanov M.B., Wikoff W.R., Zhu H., Boyle S.H., Churchill E., Wang Z., Rush A.J., Krishnan R.R., Pickering E., Delnomdedieu M., Fiehn O. Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo. Transl. Psychiatry 2013, 3:e223.
25. Kato M., Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol. Psychiatry 2010, 15:473-500.
26. Knorr U., Vinberg M., Kessing L.V., Wetterslev J. Salivary cortisol in depressed patients versus control persons: a systematic review and meta-analysis. Psychoneuroendocrinology 2010, 35:1275-1286.
27. Larrieu T., Hilal L.M., Fourrier C., De Smedt-Peyrusse V., Sans N., Capuron L., Laye S. Nutritional omega-3 modulates neuronal morphology in the prefrontal cortex along with depression-related behaviour through corticosterone secretion. Transl. Psychiatry 2014, 4:e437.
28. Laugero K.D., Smilowitz J.T., German J.B., Jarcho M.R., Mendoza S.P., Bales K.L. Plasma omega 3 polyunsaturated fatty acid status and monounsaturated fatty acids are altered by chronic social stress and predict endocrine responses to acute stress in titi monkeys. Prostaglandins Leukot. Essent. Fatty Acids 2011, 84:71-78.
29. Lee L.H., Shui G., Farooqui A.A., Wenk M.R., Tan C.H., Ong W.Y. Lipidomic analyses of the mouse brain after antidepressant treatment: evidence for endogenous release of long-chain fatty acids?. Int. J. Neuropsychopharmacol. 2009, 12:953-964.
30. Lesperance F., Frasure-Smith N., St-Andre E., Turecki G., Lesperance P., Wisniewski S.R. The efficacy of omega-3 supplementation for major depression: a randomized controlled trial. J. Clin. Psychiatry 2011, 72:1054-1062.
31. Lin P.Y., Huang S.Y., Su K.P. A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. Biol. Psychiatry 2010, 68:140-147.
32. Lin P.Y., Mischoulon D., Freeman M.P., Matsuoka Y., Hibbeln J., Belmaker R.H., Su K.P. Are omega-3 fatty acids antidepressants or just mood-improving agents? The effect depends upon diagnosis, supplement preparation, and severity of depression. Mol. Psychiatry 2012, 17:1161-1163. author reply 1163-1167.
33. Lok A., Mocking R.J., Ruhé H.G., Visser I., Koeter M.W., Assies J., Bockting C.L., Olff M., Schene A.H. Longitudinal hypothalamic-pituitary-adrenal axis trait and state effects in recurrent depression. Psychoneuroendocrinology 2012, 37:892-902.
34. Lucas M., Mirzaei F., O'Reilly E.J., Pan A., Willett W.C., Kawachi I., Koenen K., Ascherio A. Dietary intake of n-3 and n-6 fatty acids and the risk of clinical depression in women: a 10-y prospective follow-up study. Am. J. Clin. Nutr. 2011, 93:1337-1343.
35. Macfarlane D.P., Forbes S., Walker B.R. Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. J. Endocrinol. 2008, 197:189-204.
36. McNamara R.K., Able J.A., Rider T., Tso P., Jandacek R. Effect of chronic fluoxetine treatment on male and female rat erythrocyte and prefrontal cortex fatty acid composition. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34:1317-1321.
37. McNamara R.K., Strimpfel J., Jandacek R., Rider T., Tso P., Welge J.A., Strawn J.R., Delbello M.P. Detection and treatment of long-chain omega-3 fatty acid deficiency in adolescents with SSRI-resistant major depressive disorder. PharmaNutrition 2014, 2:38-46.
38. Mischoulon D., Nierenberg A.A., Schettler P.J., Kinkead B.L., Fehling K., Martinson M.A., Hyman Rapaport M. A double-blind, randomized controlled clinical trial comparing eicosapentaenoic acid versus docosahexaenoic acid for depression. J. Clin. Psychiatry 2015, 76:54-61.
39. Mocking R.J., Assies J., Bot M., Jansen E.H., Schene A.H., Pouwer F. Biological effects of add-on eicosapentaenoic acid supplementation in diabetes mellitus and co-morbid depression: a randomized controlled trial. PLoS ONE 2012, 7:e49431.
40. Mocking R.J., Assies J., Koeter M.W., Ruhé H.G., Lok A., Schene A.H. Bimodal distribution of fatty acids in recurrent major depressive disorder. Biol. Psychiatry 2012, 71:e3-e5.
41. Mocking R.J., Assies J., Lok A., Ruhé H.G., Koeter M.W., Visser I., Bockting C.L., Schene A.H. Statistical methodological issues in handling of fatty acid data: percentage or concentration, imputation and indices. Lipids 2012, 47:541-547.
42. Mocking R.J., Lok A., Assies J., Koeter M.W., Visser I., Ruhé H.G., Bockting C.L., Schene A.H. Ala54Thr fatty acid-binding protein 2 (FABP2) polymorphism in recurrent depression: associations with fatty acid concentrations and waist circumference. PLoS ONE 2013, 8:e82980.
43. Mocking R.J., Ruhé H.G., Assies J., Lok A., Koeter M.W., Visser I., Bockting C.L., Schene A.H. Relationship between the hypothalamic-pituitary-adrenal-axis and fatty acid metabolism in recurrent depression. Psychoneuroendocrinology 2013, 38:1607-1617.
44. Murck H., Song C., Horrobin D.F., Uhr M. Ethyl-eicosapentaenoate and dexamethasone resistance in therapy-refractory depression. Int. J. Neuropsychopharmacol. 2004, 7:341-349.
45. Plourde M., Chouinard-Watkins R., Rioux-Perreault C., Fortier M., Dang M.T., Allard M.J., Tremblay-Mercier J., Zhang Y., Lawrence P., Vohl M.C., Perron P., Lorrain D., Brenna J.T., Cunnane S.C. Kinetics of 13C-DHA before and during fish-oil supplementation in healthy older individuals. Am. J. Clin. Nutr. 2014, 100:105-112.
46. Rajiv C., Sarah S., Donal G., An P., Samantha W., Susmita C., Heather W., Laura J., Francesca C., Frank B.H., Oscar H.F. Association between fish consumption, long chain omega 3 fatty acids, and risk of cerebrovascular disease: systematic review and meta-analysis. BMJ 2012, 345.
47. Rosenbaum P.R., Rubin D.B. The central role of the propensity score in observational studies for causal effects. Biometrika 1983, 70:41-55.
48. Ruhé H.G., Booij J., Veltman D.J., Michel M.C., Schene A.H. Successful pharmacologic treatment of major depressive disorder attenuates amygdala activation to negative facial expressions: a functional magnetic resonance imaging study. J. Clin. Psychiatry 2012, 73:451-459.
49. Ruhé H.G., Booij J., Weert H.C., Reitsma J.B., Franssen E.J., Michel M.C., Schene A.H. Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy. Neuropsychopharmacology 2009, 34:999-1010.
50. Ruhé H.G., Khoenkhoen S.J., Ottenhof K.W., Koeter M.W., Mocking R.J., Schene A.H. Longitudinal effects of the SSRI paroxetine on salivary cortisol in Major Depressive Disorder. Psychoneuroendocrinology 2015, 52:261-271.
51. Smith K.J., Sanderson K., McNaughton S.A., Gall S.L., Dwyer T., Venn A.J. Longitudinal associations between fish consumption and depression in young adults. Am. J. Epidemiol. 2014, 179:1228-1235.
52. Stetler C., Miller G.E. Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. Psychosom. Med. 2011, 73:114-126.
53. Strom M., Mortensen E.L., Halldorsson T.I., Thorsdottir I., Olsen S.F. Fish and long-chain n-3 polyunsaturated fatty acid intakes during pregnancy and risk of postpartum depression: a prospective study based on a large national birth cohort. Am. J. Clin. Nutr. 2009, 90:149-155.
54. Trivedi M.H., Morris D.W., Grannemann B.D., Mahadi S. Symptom clusters as predictors of late response to antidepressant treatment. J. Clin. Psychiatry 2005, 66:1064-1070.
55. Uher R., Mors O., Rietschel M., Rajewska-Rager A., Petrovic A., Zobel A., Henigsberg N., Mendlewicz J., Aitchison K.J., Farmer A., McGuffin P. Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: a secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study. J. Clin. Psychiatry 2011, 72:1478-1484.
56. Vallette G., Vanet A., Sumida C., Nunez E.A. Modulatory effects of unsaturated fatty acids on the binding of glucocorticoids to rat liver glucocorticoid receptors. Endocrinology 1991, 129:1363-1369.
57. Visioli F., Rise P., Barassi M.C., Marangoni F., Galli C. Dietary intake of fish vs. formulations leads to higher plasma concentrations of n-3 fatty acids. Lipids 2003, 38:415-418.
58. Vreeburg S.A., Hoogendijk W.J., van Pelt J., Derijk R.H., Verhagen J.C., van Dyck R., Smit J.H., Zitman F.G., Penninx B.W. Major depressive disorder and hypothalamic-pituitary-adrenal axis activity: results from a large cohort study. Arch. Gen. Psychiatry 2009, 66:617-626.
59. Yager S., Forlenza M.J., Miller G.E. Depression and oxidative damage to lipids. Psychoneuroendocrinology 2010, 35:1356-1362.